Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research
deadline JUne 9, 2021
Projects that will be considered for Pfizer support will focus on several or one specified area:

• Early identification, evaluation, diagnosis, prognosis & treatment
• Study of hereditary ATTR genotypes and phenotypes (Non-Val30Met genotypes; Val122Ile, Thr60Ala, Val30Met, and others)
• Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)
• Use of tafamidis in the clinical setting (i.e. real-world evidence)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive Grant Program
deadline June 15, 2021
The diagnosis of ATTR-CM is complex and often requires patients to undergo many diagnostic procedures with multiple specialists. The nurse navigator is an important member of the healthcare team who provides care in a highly supportive and personal manner and helps to guide and support patients and their families through the patient diagnostic and treatment journey.   Projects that will be considered for funding will focus on supporting the development of nurse navigator programs, including training, in order to improve the quality of care for ATTR-CM patients.